The global proteomics market value is projected to rise substantially over 2023-2032, owing to the development of technologically advanced instruments including 2D electrophoresis protein analyzers.

The integration of engineered devices such as biochips can improve the throughput and efficiency of biological research, workflow, and speed. Such tech innovations, along with the mounting investment in protein engineering facility expansion projects, are expected to boost proteomics analysis.

Citing an instance, in February 2022, the NIH’s National Institute of General Medical Sciences announced funding to establish a Genetic Code Expansion Center in Oregon. This facility was intended to revolutionize protein-focused biomedical and material research and solidify the state’s status as a leader in the advancement of protein engineering. Initiatives such as these are likely to increase the reliance on engineered proteins for selective proteomics research applications.

The proteomics industry is categorized in terms of component, technique, application, end-use, and regional landscape.

Based on the component, the market share from the instruments segment is set to grow considerably over the forecast period. The availability of ultra-fast mass spectrometers and automated protein digestion platforms to innovate cloud-based informatics is a key contributor to molecular and cellular proteomics development.

In addition, proteomics facilities are equipped with state-of-the-art equipment and bioinformatics tools for data evaluation and interpretation. Such factors are anticipated to proliferate the advancement of proteomics technologies.

Proteomics market size from the conventional technique segment is slated to rise by 2032. This is on account of innovations in liquid chromatography that allow efficient analysis of proteomes of single cells. Several lab instrument manufacturing companies are also focused on launching chromatography solutions to support life science research, driving the adoption of clinical proteomics.

Based on the application, the industry share from the clinical diagnosis segment is poised to depict a strong growth rate through 2032, due to the surge in vaccine-preventable disease outbreaks. As per the WHO, in Africa, over 17,500 cases of measles were reported between January and March 2022, indicating a 400% rise from a year earlier. This growing disease burden is likely to increase the reliance on proteomics to discover biomarkers that indicate a particular disease.

Global proteomics industry value from the other end-use segment, including hospitals and research organizations, is projected to be worth more than USD 7.5 billion by 2032, owing to the increase in healthcare research funding.

For example, in October 2022, the NIHR Oxford BRC and the NIHR Oxford Health BRC obtained over USD 136.5 million in government funding to support 15 research themes over the next 5 years. These funds are slated to assert a positive impact on the proteomics industry outlook globally.

On the regional front, North America accounted for more than 47.5% share of the proteomics market in 2022, given the strong presence of key players and constant government support for proteomics research.
Asia Pacific proteomics industry size is also anticipated to witness an upsurge by 2032, considering the introduction of novel drug discovery projects for chronic diseases and the development of innovative mass spectrometers.